PFG Advisors Has $2.37 Million Position in Cencora, Inc. $COR

PFG Advisors grew its holdings in shares of Cencora, Inc. (NYSE:COR) by 598.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,569 shares of the company’s stock after buying an additional 6,485 shares during the quarter. PFG Advisors’ holdings in Cencora were worth $2,365,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Cencora by 4.1% in the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock valued at $7,311,810,000 after acquiring an additional 916,506 shares during the last quarter. Geode Capital Management LLC boosted its position in Cencora by 6.3% during the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after purchasing an additional 284,229 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Cencora by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock valued at $1,461,965,000 after purchasing an additional 821,098 shares in the last quarter. Norges Bank bought a new position in Cencora in the second quarter valued at approximately $695,215,000. Finally, Viking Global Investors LP increased its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after purchasing an additional 1,013,913 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 15,220 shares of company stock valued at $5,282,867 over the last ninety days. 0.38% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on COR shares. Wells Fargo & Company upped their price objective on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. Evercore lowered their target price on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Robert W. Baird set a $415.00 price target on shares of Cencora in a research report on Tuesday, January 13th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Finally, Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $399.00.

Cencora Stock Performance

COR opened at $351.97 on Wednesday. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a 12-month low of $251.94 and a 12-month high of $377.54. The business has a 50 day moving average of $354.84 and a 200-day moving average of $337.51. The stock has a market cap of $68.47 billion, a price-to-earnings ratio of 42.30, a PEG ratio of 1.69 and a beta of 0.68.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The business had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the previous year, the firm earned $3.73 EPS. The firm’s revenue was up 5.5% compared to the same quarter last year. On average, equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date was Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.